依普利酮
依普利酮结构式
|
常用名 | 依普利酮 | 英文名 | Eplerenone |
|---|---|---|---|---|
| CAS号 | 107724-20-9 | 分子量 | 414.491 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 597.9±50.0 °C at 760 mmHg | |
| 分子式 | C24H30O6 | 熔点 | 241-243ºC | |
| MSDS | 美版 | 闪点 | 259.5±30.2 °C |
|
Lung fibrosis: drug screening and disease biomarker identification with a lung slice culture model and subtracted cDNA Library.
Altern. Lab. Anim. 42(4) , 235-43, (2014) Pulmonary fibrosis is a progressive and irreversible disorder with no appropriate cure. A practical and effective experimental model that recapitulates the disease will greatly benefit the research community and, ultimately, patients. In this study, we tested... |
|
|
Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension.
Am. J. Physiol. Heart Circ. Physiol. 309 , H1987-96, (2015) The aim of the present study was to determine whether long-term high salt intake in the drinking water induces hypertension in wild-type (WT) mice and whether a chymase inhibitor or other antihypertensive drugs could reverse the increase of blood pressure. Ei... |
|
|
The Other Side of the RAAS: Aldosterone Improves Migration of Cardiac Progenitor Cells.
J. Cell Physiol. 230 , 2829-36, (2015) Stem cell therapy is a promising new option for patients suffering from heart failure. Though many clinical studies show encouraging results, little is known about the signals which cause stem cells to home to diseased but not to healthy hearts. We hypothesiz... |
|
|
Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.
FASEB J. 29 , 4544-54, (2015) Early treatment with heart failure drugs lisinopril and spironolactone improves skeletal muscle pathology in Duchenne muscular dystrophy (DMD) mouse models. The angiotensin converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagonist ... |
|
|
Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
J. Invest. Dermatol. 135 , 1781-9, (2015) A major deleterious side effect of glucocorticoids is skin atrophy. Glucocorticoids activate the glucocorticoid and the mineralocorticoid (MR) receptor, both present in the epidermis. We hypothesized that glucocorticoid-induced epidermal atrophy may be relate... |
|
|
Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation.
Mol. Cell. Endocrinol. 411 , 20-7, (2015) Interleukin-33 (IL-33) but not soluble ST2 (sST2) exerts anti-inflammatory and protective effects in several tissues. Aldosterone, a proinflammatory mediator which promotes adipogenesis, is elevated in obese patients. The aim of this study was to investigate ... |
|
|
Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts.
J. Endocrinol. 222(2) , 289-99, (2014) Although persistent excessive actions of aldosterone have unfavorable effects on the cardiovascular system, primarily via mineralocorticoid receptor (MR)-dependent pathways, the pathophysiological significance of aldosterone cascade activation in heart diseas... |
|
|
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Liver Int. 35 , 2129-38, (2015) Therapeutic options to treat Non-alcoholic steatohepatitis (NASH) are limited. Mineralocorticoid receptor (MR) activation could play a role in hepatic fibrogenesis and its modulation could be beneficial for NASH.To investigate whether eplerenone, a specific M... |
|
|
Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL).
Yonago. Acta. Med. 57(3) , 109-16, (2014) Cardiac fibrosis is considered to be a crucial factor in the development of heart failure. Blockade of the mineralocorticoid receptor (MR) attenuated cardiac fibrosis and improved the prognosis of patients with chronic heart failure but the ligand for MR and ... |
|
|
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Lancet. Diabetes Endocrinol. 2(12) , 944-53, (2015) Renin-angiotensin system inhibitors have renoprotective effects in patients with chronic kidney disease, but most patients treated with these drugs have residual urinary albumin excretion. Some small clinical studies show that mineralocorticoid receptor block... |